Florent Barbault

Dr. Florent Barbault

Université de Paris
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DKDavide Komla-Ebri
Davide Komla-Ebri
EDEmilie Dambroise
Emilie Dambroise
IKIna Kramer
Ina Kramer
CBCatherine Benoist-Lasselin
Catherine Benoist-Lasselin
NKNabil Kaci
Nabil Kaci
LLLaurence Legeai-Mallet
Laurence Legeai-Mallet
Achondroplasia (ACH) is the most frequent form of dwarfism and is caused by gain-of-function mutations in the fibroblast growth factor receptor 3–encoding (FGFR3-encoding) gene. Although potential therapeutic strategies for ACH, which aim to reduce excessive FGFR3 activation, have emerged over many years, the use of tyrosine kinase inhibitor (TKI) to counteract FGFR3 hyperactivity has yet to be evaluated. Here, we have reported that the pan-FGFR TKI, NVP-BGJ398, reduces FGFR3 phosphorylation and corrects the abnormal femoral growth plate and calvaria in organ cultures from embryos of the Fgfr3Y367C/+ mouse model of ACH. Moreover, we demonstrated that a low dose of NVP-BGJ398, injected subcutaneously, was able to penetrate into the growth plate of Fgfr3Y367C/+ mice and modify its organization. Improvements to the axial and appendicular skeletons were noticeable after 10 days of treatment and were more extensive after 15 days of treatment that started from postnatal day 1. Low-dose NVP-BGJ398 treatment reduced intervertebral disc defects of lumbar vertebrae, loss of synchondroses, and foramen-magnum shape anomalies. NVP-BGJ398 inhibited FGFR3 downstream signaling pathways, including MAPK, SOX9, STAT1, and PLCγ, in the growth plates of Fgfr3Y367C/+ mice and in cultured chondrocyte models of ACH. Together, our data demonstrate that NVP-BGJ398 corrects pathological hallmarks of ACH and support TKIs as a potential therapeutic approach for ACH.

18 November 2008 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KLKun Liu
Kun Liu
HLHong Lu
Hong Lu
LHLing Hou
Ling Hou
ZQZhi Qi
Zhi Qi
CTCátia Teixeira
Cátia Teixeira
LXLan Xie
Lan Xie

1 March 2020 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
ZMZouhour Mazouz
Zouhour Mazouz
MMMeriem Mokni
Meriem Mokni
Najla FOURATINajla FOURATI
Najla FOURATI
CZChouki Zerrouki
Chouki Zerrouki
FBFlorent Barbault
Florent Barbault
AOAli Othmane
Ali Othmane

1 December 2007 in Current Computer-Aided Drug Design
Verified
Journal Article
Closed access
JDJean-Pierre Doucet
Jean-Pierre Doucet
FBFlorent Barbault
Florent Barbault
HXHairong Xia
Hairong Xia
APAnnick Panaye
Annick Panaye
BFBotao Fan
Botao Fan
Recently, a new promising nonlinear method, the support vector machine (SVM), was proposed by Vapnik. It rapidly found numerous applications in chemistry, biochemistry and pharmacochemistry. Several attempts using SVM in drug design have been reported. It became an attractive nonlinear approach in this field. In this review, the theoretical basis of SVM in classification and regression is briefly described. Its applications in QSPR/QSAR studies, and particularly in drug design are discussed. Comparative studies with some linear and other nonlinear methods show SVMs high performance both in classification and correlation.

18 November 2003 in Biochemistry
Verified
Journal Article
Closed access
FBFlorent Barbault
Florent Barbault
CLCéline Landon
Céline Landon
MGMarc Guenneugues
Marc Guenneugues
JMJean-Philippe Meyer
Jean-Philippe Meyer
VSValérie Schott
Valérie Schott
FVFrançoise Vovelle
Françoise Vovelle

1 March 2008 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
CTCátia Teixeira
Cátia Teixeira
FBFlorent Barbault
Florent Barbault
JRJoseph S. Rebehmed
Joseph S. Rebehmed
KLKun Liu
Kun Liu
LXLan Xie
Lan Xie
FMFrançois Maurel
François Maurel